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This editorial refers to ‘Annual number of candidates for
transcatheter aortic valve implantation per country: cur-
rent estimates and future projections’†, by A.P. Durko et al.,
on page 2635.
Transcatheter aortic valve implantation (TAVI) entered the limelight
more than a decade ago as a life-saving treatment option among inop-
erable patients with severe, symptomatic aortic stenosis.1 Consistent
data in terms of safety and efficacy of TAVI compared with surgical
aortic valve replacement (SAVR) in several randomized controlled
trials across the risk spectrum propelled the rapid expansion of TAVI
to elderly patients at intermediate and high risk for SAVR. The innov-
ation related to TAVI ignited an unprecedented interest in the field of
valvular heart disease, created a momentum for transcatheter struc-
tural interventions, challenged cardiac surgery, and catalysed the for-
mation of specialized heart teams.
Aortic stenosis is the most common valvular heart disease requir-
ing intervention in high-income countries, ranging from 3.4% [95%
confidence interval (CI) 1.1–5.7%] to 12.4% (95% CI 6.6–18.2%) in
the elderly population >_75 years of age according to severity of dis-
ease,2 and accounts for the highest valve-related mortality in the
USA.3 In low- and middle-income countries, data on the prevalence
of degenerative valvular heart disease in the ageing population are
scarce and outnumbered by reports on the prevalence of rheumatic
valvular disease at the opposite end of the age spectrum.4 However,
a shift in the age distribution towards the elderly and a transition
from rheumatic to degenerative valvular heart disease in low- and
middle-income countries let us anticipate a further increase in the
global burden of aortic stenosis.5
In this issue of the European Heart Journal, Durko and colleagues
present a systematic review and meta-analysis estimating the number
of patients with severe, symptomatic aortic stenosis that may be po-
tentially eligible for TAVI in the European Union and North America
based on data from 37 studies including >26 000 patients.6 The study
refines the estimates reported in a previous publication by the same
group of authors.2 Interestingly, fewer than two-thirds of patients
with severe, symptomatic aortic stenosis that were not eligible for
SAVR actually underwent TAVI. The authors estimate that annually
180 000 patients in the European Union and North America may
qualify for TAVI according to current guidelines, and anticipate an in-
crease up to 270 000 patients per year with expansion of TAVI to
low-risk patients.
Based on these data, it is of interest to analyse the forces that will
lead to further expansion of TAVI in multiple directions at variable
speed driven by different circumstances. First, a continuous improve-
ment in procedural and long-term outcomes across all risk categories
facilitated the dispersion of TAVI into the low-risk segment of elderly
patients. This progress was related to the mitigation of the risk of par-
avalvular aortic regurgitation and the lower profile of newer gener-
ation transcatheter heart valves, as well as improved technique and
the more frequent use of the transfemoral access site (Figure 1). Of
note, while estimated risk in randomized controlled trials as assessed
by the Society of Thoracic Surgeons (STS) score continuously
decreased from 11.8% in the Placement of AoRTic TraNscathetER
Valve (PARTNER) 1A trial to 2.9% in the Nordic Aortic Valve
Intervention (NOTION) 1 trial, the mean age decreased only slightly,
ranging from 83.6 years in PARTNER 1A to 79.2 years in NOTION I
(Figure 1).7,8 The ongoing PARTNER-3 (NCT02675114), NOTION-
2 (NCT02825134), and the Evolut R low risk (NCT02701283) trials
will cumulatively enrol 3500 patients with STS scores <4 (<3 for
ELRT) into randomized controlled trials comparing TAVI with SAVR,
and will provide a solid basis of evidence for the outcomes of TAVI
among low-risk patients.
Secondly, TAVI is increasingly performed among patients with off-
label indications such as bicuspid aortic valve anatomy,9 failed surgical
bioprostheses,10 and pure native aortic valve regurgitation.11 In a
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propensity score-matched analysis of 546 matched pairs of patients
with bicuspid and tricuspid aortic stenosis, bicuspid aortic stenosis
conferred a higher risk of conversion to surgery (2.0% vs. 0.2%,
P = 0.006) and a lower device success rate (85.3% vs 91.4%, P =
0.002); however, among the subgroup of patients treated with newer
generation devices, clinical event rates were comparable with those
with tricuspid valve anatomy.9 The multinational valve-in-valve regis-
try including 459 patients with degenerated surgical bioprostheses
reported a 1-year survival rate of 83.2% after valve-in-valve TAVI.
Bioprosthetic valve stenosis was associated with a three-fold
increased risk of mortality as compared with regurgitation, and small
surgical bioprostheses (<_21 mm) doubled the risk of mortality at 1
year.10 In a multicentre registry of 331 patients with pure native aortic
valve regurgitation undergoing TAVI, all-cause mortality at 1 year
amounted to 24.1% and was determined by the extent of residual
aortic regurgitation (AR >_moderate 46.1% vs. AR <_mild 21.8%, log-
rank P = 0.001). The risk of device embolization was significantly
lower in patients treated with newer as compared with early gener-
ation devices (12.7% vs. 24.4%, P = 0.007).11 In addition to the above-
mentioned indications, transcatheter aortic valve devices have been
successfully used for the treatment of degenerated mitral valve
prostheses and failed annuloplasty rings,12 as well as mitral annular
calcification (Figure 2). At the same time, optimal timing of TAVI is re-
evaluated in randomized controlled trials. The EARLY TAVR trial
investigates TAVI for asymptomatic severe aortic stenosis compared
with watchful waiting (NCT03042104), while the TAVR UNLOAD
trial (NCT02661451) assesses the impact of TAVI in patients with
moderate aortic stenosis and heart failure with reduced ejection frac-
tion as compared with optimal heart failure therapy alone.
Thirdly, the projections provided by Durko and colleagues raise
the question of geographical and socio-economic inequalities in ac-
cess to and utilization of TAVI worldwide. An analysis from 11
European countries in 2011 showed a variation in TAVI procedures
between 6.1 in Portugal and 88.7 per million in Germany, and sug-
gested a significant correlation between TAVI use and healthcare































Figure 1 Expansion of TAVI towards the low-risk spectrum in
randomized controlled trials. Risk as assessed by the STS score is
shown on the y-axis and observed 1-year mortality is shown on the
x-axis. The size of the circles correlates with the number of patients
included in the randomized controlled trial.
Bicuspid AS ViV in aorc posion
Pure nave AR TAVI in MAC ViV in tricuspid and pulmonary posion
Figure 2 Expansion of TAVI towards off-label indications: bicus-
pid aortic stenosis, valve-in-valve in aortic position, pure native aor-
tic regurgitation, TAVR in mitral annular calcufication, and valve-in-







Take home figure Geographical dispersion of TAVI. TAVI implantation per 1 000 000 inhabitants. Estimates for Q1–Q4 2017 (Western Europe)























































































.prosperity and healthcare spending, while remaining inaccessible to
the majority of patients with severe, symptomatic aortic stenosis
worldwide. The rapid expansion of TAVI into the low-risk patient
population and off-label indications in selected countries contrast
with the low penetration of TAVI outside of North America and
Western Europe (Take home figure). Differences in the access to
medical innovation result from economic constraints, social values,
and political processes.14 More than half of all surgical procedures
globally are performed in high-income countries, whereas four out of
five deaths from cardiovascular disease occur in low- and middle-in-
come countries.15,16 Challenges in the expansion of valvular interven-
tions to less privileged regions of the world include awareness and
education, absence of resources for diagnosis and referral, lack of in-
frastructure, competing health priorities, and extortionate costs.14
Strategies to advance TAVI in these settings need to respect the local
context and include the education of physicians and healthcare per-
sonnel, the access to affordable devices, and promotion of a minimal-
istic strategy.14 Disparities in the implementation of TAVI inspired
the ‘valve for life’ initiative launched by the European Association of
Percutaneous Cardiovascular Intervention of the ESC in 2015. The
initiative aims to raise awareness of valvular heart disease, improve
educational standards for healthcare professionals and specialists,
and attenuate disparities in access to care across Europe.17
Geographic dissemination of valvular heart disease treatment to
less privileged regions of the world and strategies for equitable access
and utilization to commensurate treatment may in fact represent yet
another frontier of the TAVI revolution.
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